PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario–(Newsfile Corp. – January 14, 2026) – PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the “Company” or “PharmaTher”), a specialty pharmaceutical company focused on unlocking the therapeutic potential of ketamine, psychedelics, and GLP-1 drugs for neuropsychiatric and obesity disorders, today announced a new strategic initiative to expand its PharmaPatch™ microneedle patch platform into GLP-1 therapies for […]